188
Views
4
CrossRef citations to date
0
Altmetric
Original Article

Sequential Combination Chemotherapy (Caboppivim) for the Treatment of High-Grade Malignant Non-Hodgkin Lymphoma

, , , , , & show all
Pages 495-500 | Published online: 08 Jul 2009

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (1)

Fredrick B. Hagemeister. (1999) The Role of Ifosfamide in the Treatment of Lymphomas. Leukemia & Lymphoma 34:5-6, pages 433-441.
Read now

Articles from other publishers (3)

A. FossåA. SantoroW. HiddemannL. TruemperN. NiederleS. BuksmauiG. BonadonnaS. SeeberM. R. Nowrousian. (1999) Gemcitabine as a Single Agent in the Treatment of Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma. Journal of Clinical Oncology 17:12, pages 3786-3792.
Crossref
William S. Velasquez, Peter McLaughlin, Lillian M. Fuller, Pamela K. Allen, Susan L. Tucker, Forrest Swan, Maria A. Rodriguez, Fredrick B. Hagemeister & Fernando F. Cabanillas. (1994) Intermediate-grade lymphomas treated with cyclophosphamide-doxorubicin-vincristine-prednisone-bleomycin alternated with cyclophosphamide-methotrexate-etoposide-dexamethasone. Application of prognostic models to data analysis. Cancer 73:9, pages 2408-2416.
Crossref
Mohammad R. Nowrousian, Christof H. Anders, Norbert Niederle, Marianne Nagel-Hiemke, Thomas Moritz, Siegfried Seeber & Carl G. Schmidt. (1991) Etoposide, ifosfamide, and methotrexate with or without bleomycin in refractory or recurrent lymphomas. Annals of Oncology 2, pages 25-30.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.